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Supplementary Figure 1: The autochthonous LSL:EGFR T790M/L858R model develops 
lung adenocarcinoma in mice 
  (A) Graph of percentage of tumors in cross-sections that stained positively for SOX2.  Mean ± 
SEM is graphed, n=10 mice.  (B)  Representative immunofluorescence staining of EGFR 
T790M/L858R autochthonous lung tumors with the indicated probes. (C) Representative 
immunofluorescence staining of KrasG12D; p53-null autochthonous lung tumors with the 
indicated probes. 
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Supplementary Figure 2: Distal lung stem/progenitor cells efficiently undergo ex vivo 
malignant transformation by mutant EGFR  (A) Schematic of sorted for NGFR+ basal cells of 
the trachea, NGFR- club cells of the trachea, Sca1/Ly6A+ BASCs of the distal lung and Sca1- 
AT2 cells of the distal lung. (B) H&E and IF analysis of BASC-derived mixed organoids stained 
with the antibodies against the indicated proteins. (C) Tumor counts from each mouse with 
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indicated organoid types transplanted, mean ± SEM is graphed. (D) mRNA expression of 
human EGFR, Col1a1 and Trp53 are graphed relative to the expression in matched GFP-
control cells, n=1 biological replicate, n=2 independent qPCR experiments, mean ± SEM is 















Supplementary Figure 3: Different stem/progenitor cells drive distinct gene expression 
during malignant transformation 
 (A) H&E and IF analysis of AT2-derived alveolar and BASC-derived bronchiolar tumoroids after 
transplant stained with the indicated probes. (B) Hierarchical clustering and dendsort plot using 
Chen et al., Supplemental 6 
 
principal component analysis 1 (PC1) of the variability of gene expression of the indicated 
samples. (C) Bar plots of normalized enrichment scores of selected gene signatures enriched in 
tumoroids after transplant relative to Ad-Cre treated organoids before transplant, with FDR q-
values indicated outside the end of bars. (D) Bar plots of normalized enrichment scores of 
selected gene signatures enriched in EGFR mutant lung cancer tumors relative to normal lung 
tissues, with FDR q-values indicated outside the end of bars, q values in bold are pathways 
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Supplementary Figure 4:  Bronchiolar and alveolar tumor organoids have distinct drug 
responses  (A) Relative mRNA expression of human EGFR and Col1a1 in the indicated mouse 
3D tumoroids determined by RT-qPCR, n=6 experimental replicates for BASCs and n=5 
experimental replicates for AT2-A, mean +/- SEM is graphed. (B) PCR of genomic DNA show 
that all tumors and organoids are derived from EGFR-donor mice.  (C) Averaged IC50 of the 
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indicated drugs calculated by the log(inhibitor) versus response curves. (D) Dose responses to 
drugs erlotinib in the indicated tumoroids, n=4 experiments. (E) Percentage of survival of BASC-
A tumoroids with the indicated treatments of osimertinib 2.5 μM, EPZ-6438 5 μM, JQ1 50 nM 
and copanlisib 10 nM compared to control, mean ± SEM, n=4 for all except copanlisib n=3 
individual experiments. (F) Heatmap of Bliss synergy scores of osimertinib combined with EPZ-
6438, copanlisib, and JQ1 in PC9-GR4 2D cultures with 3 separate experiments used to 
produce the final matrix. Bliss scores with 95% confidence intervals were 11.6+/-2.6 for 
osimertinib+EPZ-6438, 9.18+/-1.79 osimertinib+copanlisib, and -9.1+/-1.43 osimertinib+JQ1.  
Most synergist area Bliss scores were 16.08 for osimertinib+EPZ6438, 17.15 for 
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Supplementary Table 1 
 
 
MSigDB Gene Set Name Descriptive Name 
HALLMARK_G2M_CHECKPOINT G2M Checkpoint 
HALLMARK_E2F_TARGETS E2F Targets 
HALLMARK_MYC_TARGETS_V1 MYC Targets 
RB_P107_DN.V1_UP RB Deletion  
HALLMARK_MTORC1_SIGNALING mTOR 
HALLMARK_DNA_REPAIR DNA Repair 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION EMT 
PRC2_EZH2_UP.V1_DN EZH2 Activating 
HALLMARK_OXIDATIVE_PHOSPHORYLATION Oxidative Phospho 
EIF4E_UP EIF4E 
PRC2_EED_UP.V1_DN EED Activating 
EGFR_UP.V1_UP EGFR 
PTEN_DN.V2_UP PTEN Deletion (Figure 3C) 
PTEN_DN.V1_UP PTEN Deletion (Figures S3 C-D) 
HALLMARK_KRAS_SIGNALING_UP KRAS Up 
HALLMARK_INFLAMMATORY_RESPONSE Inflamm Response 
P53_DN.V1_UP Mutant p53 
MEK_UP.V1_UP MEK 
HALLMARK_TNFA_SIGNALING_VIA_NFKB TNFα 
HALLMARK_KRAS_SIGNALING_DN KRAS Down 
HALLMARK_APOPTOSIS Apoptosis 
BMI1_DN.V1_UP BMI1 Deletion 
VEGF_A_UP.V1_UP VEGF-A 
TGFB_UP.V1_UP TGFβ 





HALLMARK_INTERFERON_ALPHA_RESPONSE Interferon α 
